Insider Selling: Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $854,755.68 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 157,704 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $5.42, for a total transaction of $854,755.68. Following the sale, the chief executive officer now directly owns 3,519,558 shares in the company, valued at $19,076,004.36. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Humacyte Stock Performance

HUMA opened at $5.64 on Friday. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. The stock has a market cap of $673.13 million, a price-to-earnings ratio of -5.64 and a beta of 1.47. Humacyte, Inc. has a 12-month low of $1.96 and a 12-month high of $9.97. The business has a 50 day moving average of $6.94 and a 200-day moving average of $5.54.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, equities research analysts expect that Humacyte, Inc. will post -1.09 earnings per share for the current year.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently modified their holdings of HUMA. Millennium Management LLC lifted its holdings in Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Humacyte by 28.7% during the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after buying an additional 896,415 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares during the period. Marshall Wace LLP grew its stake in shares of Humacyte by 3,301.5% in the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after acquiring an additional 450,031 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new position in Humacyte during the second quarter worth about $1,550,000. Institutional investors own 44.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on HUMA. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, September 5th. BTIG Research increased their price objective on Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 target price on shares of Humacyte in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and an average price target of $8.60.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.